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Abstract
The TGF-β cell signaling pathway functions in organism development, wound healing, skin 
function,  hair  growth,  and  tumorigenesis.  Smad2  and  Smad3  are  proteins  that  specifically 
mediate TGF-β signaling.  Previously in Dr.  Weinstein’s lab,  a  graduate student Mark Hester 
deleted  Smad4,  a  mediator  of  TGF-β signaling  downstream of  Smad2  and  Smad3,  in  skin 
fibroblasts.  He observed defects in skin development and suggested that  TGF-β signaling in 
fibroblasts was critical for skin development. Since Smad4 mediates BMP signaling as well as 
TGF-β, this project intended to determine the roles of Smad2 and Smad3 in skin development 
and tumorigenesis.
To  demonstrate  that  defects  in  skin  development  of  Smad4  mutants  are  due  to  TGF-β 
signaling, Smad2 and 3, which mediate TGF-β signaling through Smad4, were deleted in murine 
skin. Smad2 is deleted by crossing a Smad2 conditional allele with Cre transgenic mouse lines 
that express the protein either in fibroblasts or in the epithelium. Smad3 is introduced through a 
null allele. We hypothesized that if the skin defects in Smad4 mutant animals were due to defects 
in  TGF-β signaling, and not because of defects in the BMP pathway also mediated by Smad4, 
then Smad2/Smad3 mutant mice would have similar skin defects as Smad4 mutant animals. 
The first set of experiments involved Smad2 epithelial null/Smad3 null mutant animals. The 
mice are severely runted, exhibit abnormal wrinkly, scaly skin, hair loss, and die on day 16-18 
after birth. Interestingly, this phenotype is more severe than what is observed in Smad4 mutants. 
Histological  examination  of  the  skin  revealed  hyperkeratinosis  and  abnormal  hair  follicle 
positioning and cycling. A second set of experiments involved Smad3 heterozygous mice with 
the Smad2 gene knocked out only in fibroblasts. Smad3 heterozygous mice were used because 
Smad3 null, Smad2 fibroblast-null animals die before birth. These mice initially appear normal; 
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however, they develop skin and oral cancerous lesions as adults. This finding is in agreement 
with others who have observed skin and oral lesions in Smad4 mutant animals.
Comparison of skin and tumor histology using H&E staining revealed similarities in the 
phenotypes  of  Smad4  and  Smad2/Smad3  mutants.  TUNEL staining,  a  technique  that  marks 
apoptotic  cells  revealed  increased  levels  of  apoptosis  in  the  skin  of  mutants.  Ki67 
imminohistochemistry, a marker for dividing cells, revealed cell proliferation abnormalities in 
the mutants. Masson’s trichrome staining detected decreases in skin collagen fibers in epithelial 
mutants. Skin lesion progression was visualized microscopically with H&E staining. Lastly, RT-
PCR was performed on skin samples and tumors of Smad3 heterozygous, Smad2 fibroblast-null 
mutant mice to assess the level of TGF-β transcription. Expression of several TGF-β target genes 
was  shown  to  be  up-regulated  in  tumors  of  FSP:Cre;  Smad2fl/fl;Smad3+/-  mice  including: 
fibronectin, MMP-2, MMP-9, Snail, and Smad7.
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Introduction
TGF-β Pathway
The  transforming  growth  factor-beta  (TGF-β)  is  a  ubiquitous  superfamily  of  ligands 
consisting of a protein set that regulates a variety of processes during prenatal development, 
including cell  differentiation,  development,  angiogenesis,  cell  proliferation,  and apoptosis.  In 
adult organisms TGF-β regulates immune responses and homeostasis, promotes wound healing, 
and either suppresses or promotes tumorigenesis. 
The  TGF-β  signaling  pathway  begins  when  an  extracellular  ligand  binds  to  a 
transmembrane type II receptor at the cell surface [Figure 1], which activates the serine/threonine 
kinase  domain  of  the  receptor.  The  activated  receptor  then  recruits  a  complimentary 
transmembrane  Type  I  receptor  and  phosphorylates  its  glycine/serine  domain.  The 
phosphorylation activates Type I receptor’s serine/threonine kinase, which then recognizes and 
phosphorylates a Serine Serine X Serine (SSXS) motif on the Mad homology 2 (MH2) domain 
of receptor-regulated Smad proteins (rSmads), Smad2 and Smad3. After phosphorylation, either 
one of the rSmads can form a complex with the co-Smad, Smad4 [2, 3]. The r-Smad-co-Smad 
complex then migrates to the nucleus where it activates or represses target gene transcription [1]. 
The complex will bind either with transcriptional co-activators (p300) and promote transcription, 
or with transcriptional co-repressors (TGIF) and repress transcription [2]. It should be noted that 
Smad4 can also  regulate  signaling  from other  pathways,  such  as  bone  morphogenic  protein 
(BMP) and activin pathways through a separate group of rSmads, including Smad1,-5, and –8. 
Interest  in  Smad proteins  and  TGF-β signaling in  general  has  skyrocketed following 
several reports implicating a role of various Smads in tumorigenesis. Abnormalities in all Smads 
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of the TGF-β/activin pathway have been reported in various tumors. For example, the common 
Smad, Smad4, has been shown to be mutated in 50% of pancreatic tumor cases [4, 5]. Smad2 is 
under expressed in head and neck carcinomas, while some lung and colorectal cancers have been 
related  to  a  null  Smad2  mutation  ([6],  [7]).  The  loss  of  Smad3  is  linked  to  increasing 
susceptibility to human gastric cancer [8], while Smad3 null mice develop metastatic colorectal 
cancer [9].
The role of TGF-β in skin development and healing continues to be a topic of active 
research. Studies have shown that TGF-β is involved in the activation of fibroblasts, which are 
the  main  collagen-producing  cells  and  are  therefore  essential  to  skin  development  and 
maintenance, particularly the dermis layer [1]. Research with wounds and burns has consistently 
shown that TGF-β is capable of speeding up the healing process not only if applied topically 
after injury, but also if administered internally before the injury occurs [3].  
The  role  of  Smad4,  the  mediator  of  TGF-β  pathway,  has  been  investigated  by  Dr. 
Weinstein’s graduate student Mark Hester.  As a part  of his  doctorate dissertation, he studied 
mutant mice in which Smad4 was deleted in skin fibroblasts. The animals had wrinkly, scaly 
skin,  complete loss of hair by day 40, and most of them died by day 50. Upon histological 
examination  of  the  skin,  Mark  found  that  the  mutants  had  multiple  dermal  cysts, 
hyperkeratinosis, and enlarged, disoriented hair follicles that did not properly go through hair 
follicle development cycle. Immunohistochemistry results showed both increased proliferation 
and decreased apoptosis of keratinocytes around hair follicles. Mark concluded that Smad4 is 
essential  for  proper  hair  follicle  functioning.  Specifically,  he  implicated  Smad4  in  follicles’ 
entering of the catagen stage (a stage in which cell death normally takes place), as well as cell 
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proliferation control. Mark also hypothesized, but never tested, that Smad2 and Smad3 together 
might function in the patterning of the endoderm layer of the skin. 
The purpose of this project was to specifically investigate the roles of Smad2 and Smad3 
in  mouse  skin  development  and  to  compare  observed  phenotypes  of  Smad2  and  Smad3 
conditional  mutants  to  that  of  Smad4.  Mice that  are  Smad2 null  or  Smad2 heterozygous in 
combination with either Smad3 null or heterozygous are not viable. When only one of the Smads 
is lacking (either  Smad2+/- or  Smad3-/-  genotype),  the animals survive. Therefore, an approach 
involving a combination of Smad2 with Smad3 mutations should be used in order to characterize 
the phenotypes and infer the function of Smad2 and Smad3. 
Another  option  is  to  create  conditional  knockouts  with  Cre-LoxP  system.  Cre 
recombinase  of  the  P1  bacteriophage  is  a  member  of  the  integrase  family  of  site-specific 
recombinases.  Cre recombinase catalyzes recombination between two recognition sites called 
loxP sites.  The use of Cre-LoxP system allows for creation of conditional knockouts. In this 
project, FSP and MMTV conditional knockouts were introduced into Smad2. FSP-1 is fibroblast-
specific  protein-1,  and  FSP-1:Cre  is  a  fibroblast-specific  knockout,  which  deletes  Smad2 in 
fibroblasts of transgenic animals. In his unpublished dissertational work, Mark Hester showed 
successful  deletion of  Smad4 with  FSP-1:Cre  in  mice.  Specifically,  mice  lacking Smad4 in 
fibroblasts were obtained by crossing mice carrying a Smad4-null conditional allele to transgenic 
animals  carrying  the  Cre  recombinase  transgene  under  the  control  of  the  FSP-1  promoter. 
MMTV is a mouse mammary tumor virus. MMTV:Cre knockouts delete Smad2 in mammary 
tissue  and  skin.  In  order  to  create  FSP:Cre;  Smad2fl/fl;Smad3+/-  and  MMTV:Cre;  Smad2fl/fl;  
Smad3-/- genotypes used in this project, Smad2 is deleted by crossing a Smad2 conditional allele 
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with Cre transgenic mouse lines under the control of either FSP-1 or MMTV promoter. Smad3 is 
introduced through a null allele.
Skin
Mammalian skin consists of 3 major layers: epidermis (top layer), dermis (middle layer), 
and hypodermis (deepest layer) [Figure 2]. The epidermis is the outer layer of skin with variable 
thickness between species. It contains 5 layers: strata basale, spinosum, granulosum, lucidum, 
and corneum. Stratum basale, the deepest layer, has column-shaped cells, which divide, move up 
to  higher  layers,  and  flatten  out.  Stratum  corneum,  the  top  layer,  is  made  of  dead  cells 
(keratinocytes) that shed periodically. The dermis also varies in thickness. It consists of collagen, 
elastic extracellular matrix, and reticular fibers, and is divided into reticular and papillary layers. 
Hair follicles, sebaceous glands, sweat glands, apocrine glands, and blood vessels. Beneath the 
dermis lies the hypodermis, which is not considered to be part of skin, but rather subcutaneous 
tissue. The hypodermis consists mainly of loose connective tissue and adipocytes [30]. 
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Results
General condition of mutant animals
Comparison between Smad4 and Smad2/Smad3 mutant animals was made on various 
levels. On a macroscopic scale, adult mice were compared in terms of size, skin, hair, and tumor 
presence [Figure 3]. FSP:Cre; Smad4fl/fl mice are significantly smaller in size compared to wild 
type. By day 65, they exhibit wrinkly, scaly skin and loss of hair.  MMTV:Cre; Smad4fl/fl mutant 
mice are not as runted as FSP:Cre; Smad4fl/fl, but also exhibit wrinkly, scaly skin and loss of hair. 
MMTV:Cre;  Smad2fl/fl;  Smad3-/- phenotype  resembles  both  of  the  Smad4 mutant  phenotypes. 
Again, mutant animals are runted, with skin abnormalities and hair loss. In contrast,  FSP:Cre; 
Smad2fl/fl;Smad3+/- mutants do not lose hair but develop oral tumors and skin lesions as adults. 
Comparison of skin histology
A second  level  of  comparison  involved  H&E staining  of  skin  sections  of  FSP:Cre; 
Smad2fl/fl;Smad3+/-,  MMTV:Cre;  Smad2fl/fl;  Smad3-/-,  MMTV:Cre;  Smad4fl/fl,  and  FSP:Cre; 
Smad4fl/fl  mutants.  Stained  sections  of  mutant  and  wild-type  mice  were  photographed  and 
compared.
In wild-type skin, epidermis, dermis, and hypodermis are normally-thick [Figure 4-a]. 
There is a thin keratin layer on top of the epidermis, which corresponds to proper layering. Hair 
follicles  are  originating  in  the  hypodermis  and  extending  into  the  dermis  -  their  proper 
orientation.  FSP:Cre; Smad4fl/fl mutant exhibits keratin build up in the epidermis/dermis layer. 
Hair follicles seem disoriented: they are not oriented in the hypodermis as in the wild-type and 
their  positioning  is  quite  random [Figure  4-b]. MMTV:Cre;  Smad4fl/fl skin  shows  epidermal 
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hyperplasia, as well as overall disruption of epidermal layer structure [Figure 4-d].  FSP:Cre; 
Smad2fl/fl;Smad3+/- skin exhibits major epidermal hyperplasia and disoriented hair follicles in the 
dermis layer [Figure 4-c].  MMTV:Cre; Smad2fl/fl; Smad3-/- skin shows epidermal hyperplasia 
and hyperkeratinosis [Figure 4-e], both features found in FSP:Cre; Smad4fl/fl; mutant. 
 Based on the observations of skin histology, both Smad4 mutants exhibit abnormalities 
comparable  to  those  observed  in  Smad2/Smad3  mutant  animals.  Epidermal  hyperplasia  is 
common between  MMTV:Cre; Smad4fl/fl and both Smad2/Smad 3 mutants. Hyperkeratinosis is 
common between FSP:Cre; Smad4fl/fl and MMTV:Cre; Smad2fl/fl; Smad3-/- mutants. Hair follicle 
disorientation is common between both fibroblast mutants. 
In addition to H&E, Masson’s Trichrome staining was performed in order to compare 
collagen levels in MMTV:Cre; Smad2fl/fl; Smad3-/- mutant skin to wild-type skin [Figure 5]. The 
procedure  revealed  significant  decrease  in  collagen  levels  in  mutant  animals.  The  decrease 
explains the wrinkly and non-elastic nature of the mutant skin.
Apoptosis and proliferation level assessment
Since TGF-β is known to play a role in apoptosis and cell proliferation, levels of both 
were  assessed  and  compared  in  FSP:Cre;  Smad4fl/fl,  FSP:Cre;  Smad2fl/fl;Smad3+/-,  and 
MMTV:Cre; Smad2fl/fl; Smad3-/- mutant skin.  Levels of apoptosis were assessed using TUNEL 
staining procedure,  which labels DNA strand breaks that occur during apoptosis. The results 
revealed increased apoptosis of cells in the skin, especially around hair follicles, in  FSP:Cre; 
Smad4fl/fl, FSP:Cre; Smad2fl/fl;Smad3+/-,  and  MMTV:Cre; Smad2fl/fl; Smad3-/- mutants. Apoptosis 
levels in wild-type skin were minimal [Figure 6]. MMTV:Cre; Smad2fl/fl;Smad3-/- mutant seemed 
to show the highest  levels of  apoptosis.  Even though increased apoptosis  was  shown in the 
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samples used, it should be noted that skin exhibits different levels of apoptosis depending on the 
stage of the hair follicle cycle. Therefore, in order to assess the levels of apoptosis between 
mutants with certainty, larger sample with a control for timing is needed.
Ki67 imminohistochemistry was done to assess the levels of cell proliferation. Although 
in some cases there appeared to be a difference in proliferation between the mutants, there were 
not  enough samples  to  confirm the  results.  It  is  possible  that  the  animals  were  sampled  at 
different stages of the hair follicle cycle, and therefore the results captured typical proliferation 
levels of different stages. 
Oral tumors, skin lesions, and lung metastases
Both Smad4 and Smad2/3 mutant types exhibit oral tumors. In  MMTV:Cre; Smad2fl/fl;  
Smad3-/-  and FSP:Cre; Smad2fl/fl;Smad3+/-  mutants used in this project, oral tumors metastasized 
to lungs. Anywhere from 1 to a dozen lung metastases were found at a time. Lungs are a typical 
metastasis  place in mice,  just  like bone is typical for humans. Usually one or a couple skin 
lesions  were  observed  on  both  Smad2/Smad3  mutants.  The  lesions  are  characteristic  of 
squamous cell carcinomas: they resemble an open wound with occasional bleeding.  
Oral Tumor and Skin Lesion Histology
The next step involved comparing oral tumors and skin lesions on a microscopic scale. 
First,  histology  of  oral  tumors  was  compared  for  FSP:Cre;  Smad4fl/fl,  FSP:Cre;  
Smad2fl/fl;Smad3+/-,  and MMTV:Cre; Smad2fl/fl; Smad3-/- mutants using H&E staining [Figure 9]. 
Tumors  from Smad2 and Smad3 mutant  animals  exhibit  common features.  The tumor from 
FSP:Cre; Smad4fl/fl mutant resembles MMTV:Cre; Smad2fl/fl; Smad3-/-. Such results might imply a 
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similar nature of tumors in the three mutants; however, more samples would be needed to allow 
for deeper comparison. It should be noted that FSP:Cre; Smad4fl/fl  animal tumors develop much 
later than the tumors in Smad2/Smad3 mutants. Therefore, their histology would be expected to 
differ.
 Next, progression of skin lesions from normal skin to carcinomas was illustrated with 
H&E staining of three different skin sections from FSP:Cre; Smad2fl/fl;Smad3+/- and MMTV:Cre;  
Smad2fl/fl; Smad3-/- mutants [Figure 10]. The first section is normal skin that was taken from a 
mutant animal with progressed carcinoma, at least 1 inch from the actual lesion. Even though the 
skin appears normal on the surface, epidermal hyperplasia is already revealed with histology. 
Small nodules are also beginning to build up. The second section was taken closer to the border 
between normal-looking skin and the lesion. Finally, the third section was taken from the lesion 
itself. Overall,  FSP:Cre; Smad2fl/fl;Smad3+/- mutant exhibits more dramatic pathology: epidermal 
hyperplasia is more severe and there is complete disruption of the epidermis layer in the lesion 
itself. Epidermis disruption is characteristic of carcinoma. Though not as severe,  MMTV:Cre;  
Smad2fl/fl;  Smad3-/- mutant  also  exhibits  major  skin  abnormalities  leading  to  lesions. Slight 
epidermal hyperplasia is observed. The size of the nodules is also progressively increasing closer 
to the lesion.  
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TGF-β target gene transcription
Finally, levels of transcription of TGF-β target genes in tumors versus skin of FSP:Cre; 
Smad2fl/fl;Smad3+/- mutants  were  assessed  with  RT-PCR  [Figure  11].  L34  is  a  transcript  of  a 
ribosomal protein and served as a control to show high expression in both tumors and skin. Snail 
is a gene involved in epithelial-mesenchymal transition and is expressed in invasive tumors. The 
gene was up-regulated in tumors, while its expression was absent in the skin. Mmp-2 and Mmp-9 
are matrix metallo-proteinases. They degrade extracellular matrix around tumors and promote 
tumor invasion. Mmp-2 showed slight expression in the skin, but the expression in tumors was 
much higher. Mmp-9 showed elevated expression in tumors only. Smad7 is an inhibitor of TGF-
β and is up-regulated in response to TGF-β signaling. Its expression was also up-regulated in 
tumors  and absent  in  the  skin.  Fibronectin  is  a  component  of  extracellular  matrix,  and was 
expressed in both tumors and skin, with slightly more expression in tumors. 
Discussion
Macro- and microscopic examination of Smad4 and Smad2/Smad3 mutants reveals 
similarities in phenotypes
As mentioned earlier, the major goal of this project was to compare the functional roles 
of Smad4 versus Smad2 and Smad3 in three classes of mutants: FSP:Cre; Smad4fl/fl, MMTV:Cre;  
Smad2fl/fl; Smad3-/+,  and FSP:Cre; Smad2fl/fl;Smad3+/-. The roles of Smad2 and Smad3 in mouse 
skin development were assessed by observing the phenotypes of Smad2/Smad3 mutant alleles. 
Although not as insightful, similarities in general appearance of the three mutant animals started 
this project on track to more levels of comparison. Deletion of either Smad4, or Smad2 and 
Smad3 in conjunction resulted in wrinkly, scaly skin, severe growth retardation, and hair loss. 
14
Skin and tumor histochemistry results revealed that, although not identical, the phenotypes of 
FSP:Cre;  Smad4fl/fl,  MMTV:Cre;  Smad2fl/fl;  Smad3-/+,  and  FSP:Cre;  Smad2fl/fl;Smad3+/-  show 
multiple  similarities.  Hyperkeratinosis,  epidermal  hyperplasia,  dermal  cysts,  and hair  follicle 
disorientation are the main defining features of the skin of all three mutants. Tumor histology 
analysis, where tumors from FSP:Cre; Smad4fl/fl, MMTV:Cre; Smad2fl/fl; Smad3-/+, and FSP:Cre; 
Smad2fl/fl;Smad3+/-  mutant animals were compared, revealed major similarities between the two 
Smad2/Smad3 mutants. Smad4 mutant histology was similar to  MMTV:Cre; Smad2fl/fl; Smad3-
/+,in some aspects. However, more samples have to be compared to allow for a more complete 
description. As previously stated, Smad4 is a Smad common to all TGF-β superfamily pathways, 
while  Smad2  and  Smad3  exclusively  mediate  TGF-β  and  activin.  Based  on  the  phenotype 
similarities we saw in the skin, we concluded that the defects that Mark Hester observed in his 
FSP:Cre;Smad4fl/fl mutants can be attributed to defects in TGF-β signaling, and not BMP signaling 
which is also mediated by Smad4.  
Oral Tumors
Oral tumors observed in mutant animals are unique because they are the first case of oral tumors 
from a genetic knockout. Previous research has shown that  TGF-β over-expression can aid in 
pre-existing tumor  regression  [28],  but  it  was  never  shown to  be  the  cause  of  oral  tumors. 
Moreover, the oral tumors in this study were shown to metastasize to lungs, another unexpected 
finding. 
An interesting result was up-regulation of TGF-β target genes in tumors compared to the skin, 
especially considering the fact that over-expression of TGF-β has been shown to cause tumor 
regresson. [28]. Even though TGF-β regulators were inhibited, TGF-β target genes were still 
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upregulated, which was quite unexpected. Further research is needed to explain this result. For 
now, an unknown compensatory mechanism with a way to turn on TGF-β despite the r-Smad 
knockout was suggested.
Overall,  the results presented in this paper show an independent effect of Smad2/Smad3 and 
Smad4. Smad2/Smad3 mutants exhibit a more severe phenotype in some aspects, such as early 
oral  tumor growth and skin abnormalities.  Moreover,  FSP:Cre;  Smad4fl/fl  mutants  are  viable, 
while  FSP:Cre;Smad2fl/fl; Smad3-/-  are  embryonic  lethal.  This  suggests  that  Smad2/Smad3 
mutant  phenotype  is  a  lot  more  severe,  and  that  there  is  a  possibility  of  Smad2/Smad3 
independent participation. Perhaps this finding could challenge the existing knowledge of the 
pathway – that Smad2 and Smad3 are upstream and do less in TGF-β than Smad4. It should be 
noted that  FSP:Cre; Smad4fl/fl  mutant used for comparison in this study is  conditional,  while 
FSP:Cre;Smad2fl/fl; Smad3-/-  mutant  is  constitutive,  which  might  partially  explain  why 
Smad2/Smad3 phenotype is more severe [33]. However, a conclusion of their independent action 
can still be made, and this project was the first to show such action in both tumors and skin.
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Future Direction
Just because our conditional Smad2/Smad3 mutants produced a phenotype similar to the one 
produced  by Smad4  conditional  mutant,  we  cannot  with  certainty  conclude  that  the  defects 
observed in FSP:Cre; Smad4fl/fl; are due solely to TGF-β signaling defects. The pathway could act 
synergistically with other TGF-β pathways and their components. Therefore, a suggestion for 
future research would be to create the same conditional knock-outs for Smads that specifically 
mediate the BMP pathway, such as Smad1, Smad5, and Smad8. Such knockouts are feasible, but 
have not been done. It would be interesting to see how mutant phenotypes of Smad1, Smad5, and 
Smad8  individually  or  in  combination  would  compare  to  both  Smad4  and  Smad2/Smad3 
conditional mutants. 
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Materials and Methods
Genotyping of mice: Agarose gel electrophoresis was used to analyze all samples after PCR 
amplification.
Toe DNA: DNA was extracted from toes of mice using a lysis/buffer system.
PCR: Smad2 genotyping was done with primers AA and left. Smad3 genotyping was done with 
primers 5 and 7. Smad4 genotyping was done with primers CoA-1 and CoB-1. Cre-1 genotyping 
was done with primers 1 and 3 (Table 2). Reactions are run with 35 cycles with an annealing 
temperature of 55°C. 
RT-PCR:  RNA was isolated  from tissue  flash  frozen  on dry ice  using  TRIzol  reagent  (Invitrogen) 
according to manufacturer’s protocol.  cDNA was prepared using a SuperScript III First-Strand Synthesis 
System (Invitrogen).  Semi-quantitative reverse transcriptase (RT) PCR was used to assess expression of 
TGF-ß target genes following induction by TGF-ß1 treatment. Performed with primers listed in table 3. 
Hematoxylin and Eossin (H&E) stain: Done in the lab following a regular staining protocol.
Masson’s Trichrome: Done at the pathology core facility, The Ohio State University College of 
Veterinary Medicine
Ki67 Imminohistochemistry: Assesses cell proliferation by the detection of Ki67 antigen. The 
polyclonal antibody (NCL-Ki67p) labels Ki67 antigen during late G1, S, G2 and M stages of cell 
cycle. Reagents: Ki67 anti-body, 1:100 dilution (Santa Cruz, sc 7846, #K3004 goat polyclonal 
IgG), Vectastain ABC kit (Vector labs, PK-6105), DAB kit (Vector labs SK-4100). Performed 
following manufacture’s protocol. 
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TUNEL: Detects and quantifies apoptosis based on labeling of DNA strand breaks. Cleavage of 
DNA during apoptosis is identified by labeling free 3’-OH terminal with modified nucleotides in 
an  enzymatic  reaction. Reagents:  Proteinase  K,  TdT,  FITC-Avidin  D.  Performed  following 
manufacture’s protocol.
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Table 2. Primers used to genotype mice.
Primer Sequence 5'-3'
CRE-1 CGTGTTTTGCACGTTCACCG
CRE-3 ATGCTTCTGTCCGTTTGCCG
Smad2-AA GTCACTCCCTGAACCTGAAG
Smad2-Left TACTTGGGGCAATCTTTTCG
Sm3-5 CAACTTCATTGCCATATGCCCT
Sm3-7
Sm4CoA-1
CCCGAACAGTTGGATTCACACA
AAGAGCCACAGGGTCA
Sm4 CoB-1 TTCCAGGAAAAACAGGGCTA
26
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